Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

Ann Hematol · 2023 · PMC10640411 · PMID 37792065

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

General condition and symptom burden during RUX treatment ECOG performance status of patients showed a trend towards improvement after RUX treatment (16.5% of patients with ECOG 2–4 at baseline vs 12.7% at Month 36), with the proportion of patients with no restrictions (ECOG 0) increasing over time (29.9% at baseline vs 43.7% at Month 36).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.